271 related articles for article (PubMed ID: 33781112)
21. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
22. 2021 update on thyroid-associated ophthalmopathy.
Neag EJ; Smith TJ
J Endocrinol Invest; 2022 Feb; 45(2):235-259. PubMed ID: 34417736
[TBL] [Abstract][Full Text] [Related]
23. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
Hoang TD; Nguyen NT; Chou E; Shakir MK
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
[TBL] [Abstract][Full Text] [Related]
25. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
Kossler AL; Douglas R; Dosiou C
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
[TBL] [Abstract][Full Text] [Related]
26. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
[TBL] [Abstract][Full Text] [Related]
27. A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease.
Allen RC; Bradley EA; Fante RG; Lucarelli MJ
Ophthalmology; 2021 Aug; 128(8):1125-1128. PubMed ID: 33823982
[No Abstract] [Full Text] [Related]
28. A New Era in the Treatment of Thyroid Eye Disease.
Patel A; Yang H; Douglas RS
Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
[TBL] [Abstract][Full Text] [Related]
29. Treating Thyroid Associated Ophthalmopathy in Pediatric Patients.
Dong T; Fu Z; Wang X
Front Endocrinol (Lausanne); 2022; 13():900204. PubMed ID: 35837312
[TBL] [Abstract][Full Text] [Related]
30. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
31. The Adverse Effects Profile of Teprotumumab.
Stan MN; Krieger CC
J Clin Endocrinol Metab; 2023 Aug; 108(9):e654-e662. PubMed ID: 37071658
[TBL] [Abstract][Full Text] [Related]
32. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
Bartalena L; Marinò M; Marcocci C; Tanda ML
J Endocrinol Invest; 2022 Jul; 45(7):1455-1457. PubMed ID: 35403994
[No Abstract] [Full Text] [Related]
33. Teprotumumab (Tepezza) for thyroid eye disease.
Med Lett Drugs Ther; 2021 May; 63(1625):87-88. PubMed ID: 34101720
[No Abstract] [Full Text] [Related]
34. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
Chen H; Mester T; Raychaudhuri N; Kauh CY; Gupta S; Smith TJ; Douglas RS
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
36. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.
Hwang CJ; Nichols EE; Chon BH; Perry JD
Eur J Ophthalmol; 2022 May; 32(3):NP46-NP49. PubMed ID: 33525898
[TBL] [Abstract][Full Text] [Related]
37. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
Ugradar S; Kossler AL; Douglas R; Cockerham K
J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
[TBL] [Abstract][Full Text] [Related]
38. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
[TBL] [Abstract][Full Text] [Related]
39. The Role of Insulin-like Growth Factor-1 and Its Receptor in the Eye: A Review and Implications for IGF-1R Inhibition.
Truong T; Silkiss RZ
Ophthalmic Plast Reconstr Surg; 2023 Jan-Feb 01; 39(1):4-12. PubMed ID: 36598389
[TBL] [Abstract][Full Text] [Related]
40. A Review of Novel Medical Treatments for Thyroid Eye Disease.
Park JW; Yoon JS
Korean J Ophthalmol; 2024 Jun; 38(3):249-259. PubMed ID: 38773958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
